吉西他滨与长春瑞滨联合化疗治疗39例复发的铂类敏感卵巢癌临床分析  

Efficacy and tolerability of combination of gemcitabin and vinorelbine in treatment of platinum sensitive recurrent ovarian cancer

作　　者：吴玉萍 陈江鸿[2] 

机构地区：[1]湖北省武汉市江夏区第一人民医院妇产科,430200 [2]广西医科大学附属第四医院妇产科,广西柳州545005

出　　处：《重庆医学》2011年第8期806-808,共3页Chongqing medicine

摘　　要：目的探讨吉西他滨和长春瑞滨联合化疗方案治疗铂类敏感的复发卵巢上皮性癌的有效性和安全性。方法将2004年8月至2008年2月江夏区人民医院治疗的铂类敏感的复发卵巢癌患者39例（已行一线或二线及以上的以铂类为基础的化疗）,均行吉西他宾和长春瑞宾联合化疗方案（其中吉西他滨1 000 mg/m^2,长春瑞滨25 mg/m^2）化疗,第1天和第8天给药,每21天为1个疗程。以CA125水平评估化疗反应效果;毒副反应的评估依据国家癌症研究院普通毒副反应标准。结果 13例患者（33.3%）无铂类间隔（PFI）是6-12个月,超过12个月的有26例患者（66.7%）。总有效率为48.7%,完全缓解6例.中位反应时间为38周。PFI 6-12周的反应率为33.3%,66.7%的PFI〉12个月。主要的毒副反应为骨髓抑制,23%的患者有3或4级中性粒细胞减少。结论吉西他滨与长春瑞滨联合化疗方案用于铂类敏感的复发卵巢癌患者是有效的,毒副反应可以忍受。Objective To study the efficacy and tolerability of the combination of gemcitabin and vinorelbine in treatment of platinum sensitive recurrent ovarian cancer.MethodsThe patients with platinum-sensitive disease recurring after 1 or more lines of platinum-based chemotherapy were included.Vinorelbine at 25 mg/m^2 followed by gemcitabine at 1000 mg/m^2 was administered intravenously on 1 d and 8 d every 3 weeks.Response Evaluation Criteria in Solid Tumors and cancer antigen 125 test（CA-125 Kinetics[Rustin criteria]） were adopted to classify responses.Toxicity was assessed according to the National Cancer Institute Common Toxicity Criteria.ResultsThirty-nine patients were eligible.Platinum-free interval（PFI） was 6 to 12 months in 13 patients（33.3%;PFI 6-12） and more than 12 months in 26 patients（66.7%;PFI 9-12）.The overall response rate was 48.7%,with 6 complete responses.Median response duration was 38 weeks.The response rate was 23% in PFI 6-12 and 62% in PFI〉12.The most frequently observed toxicity was hematological,with 23% of the patients having grade 3 or 4 neutropenia.ConclusionGemcitabine and vinorelbine combination is effective and well tolerated in recurrent platinum-sensitive ovarian cancer.

关 键 词：卵巢肿瘤 复发疾病 铂类敏感 吉西他宾 长春瑞宾 

分 类 号：R737.31[医药卫生—肿瘤]